What is DeplinPro (L‑methylfolate) and what are the recommended dosing guidelines for treating folate deficiency and as adjunctive therapy for major depressive disorder?

DeplinPro (L-methylfolate): Product Information and Dosing Guidelines

DeplinPro is a prescription medical food containing L-methylfolate (the active form of folate) used as adjunctive therapy for major depressive disorder in patients with inadequate response to antidepressants, with a recommended dose of 15 mg daily.

What is DeplinPro?

DeplinPro contains L-methylfolate, the biologically active form of folate that crosses the blood-brain barrier and serves as a cofactor in monoamine neurotransmitter synthesis (serotonin, norepinephrine, dopamine). Unlike folic acid, L-methylfolate does not require conversion by the MTHFR enzyme, making it immediately bioavailable for neurotransmitter production 1, 2.

Important distinction: The FDA drug label evidence 3 provided refers to DEPO-PROVERA (medroxyprogesterone acetate), NOT DeplinPro. This appears to be a database error. DeplinPro is a medical food, not an FDA-approved drug, and is not used for endometrial/renal carcinoma.

Clinical Indications

For Major Depressive Disorder (Adjunctive Therapy)

L-methylfolate should be used as adjunctive therapy with antidepressants, not as monotherapy, in patients who have inadequate response to SSRI or SNRI treatment 4. The evidence supports:

• Augmentation strategy: Adding L-methylfolate when a prior antidepressant's effect is inadequate
• Acceleration strategy: Adding L-methylfolate at the beginning of treatment concurrently with an antidepressant

The strongest evidence comes from two randomized controlled trials showing that 15 mg daily L-methylfolate significantly improved response rates compared to placebo when added to SSRIs 4.

Dosing Guidelines

Standard Dosing Protocol

Start with 15 mg daily as the target therapeutic dose 4. The evidence is clear:

• 7.5 mg daily: Showed no significant benefit in the first trial 4
• 15 mg daily: Demonstrated significant efficacy with number needed to treat of approximately 6 4

Titration Strategy

For patients starting treatment:

• Begin at 15 mg daily (no need for gradual titration based on trial data)
• Continue for minimum 60 days to assess response 4
• Maintain constant antidepressant dosing during L-methylfolate initiation

Duration of Treatment

• Acute treatment: Minimum 8 weeks (60 days) to assess response 1, 4
• Maintenance: Continue indefinitely if response achieved, as part of ongoing antidepressant regimen
• Average time to response in real-world settings: 95 days 1

Patient Selection: Who Benefits Most?

L-methylfolate shows enhanced efficacy in specific patient subgroups 2, 5:

High-Priority Candidates:

• BMI ≥30 kg/m² (obesity) - significantly greater response 5
• Elevated inflammatory markers (high-sensitivity C-reactive protein) 5
• MTHFR C677T genetic variants (C/T or T/T genotypes) - though pediatric data shows mixed results 6
• Low SAMe/SAH ratio (methylation dysfunction) 5
• Elevated oxidative stress markers (4-hydroxy-2-nonenal) 5

Clinical Context:

Inflammation increases proinflammatory cytokines that interfere with monoamine neurotransmitter synthesis. L-methylfolate facilitates tetrahydrobiopterin (BH4) synthesis, a critical coenzyme in neurotransmitter production, potentially mitigating inflammatory effects on mood 2.

Expected Outcomes

Response Rates:

• 67.9% response rate (≥50% symptom reduction) in real-world study 1
• 45.7% remission rate (PHQ-9 <5) after ~95 days 1
• Mean PHQ-9 reduction: 8.5 points (58.2% decrease from baseline) 1

Meta-Analysis Results:

• Relative risk for response: 1.25 (95% CI: 1.08-1.46) favoring L-methylfolate 7
• Standardized mean difference: -0.38 (95% CI: -0.59 to -0.17) on continuous depression measures 7

Safety Profile

L-methylfolate is well-tolerated with adverse event rates similar to placebo 4:

• No weight gain (unlike atypical antipsychotics used for augmentation)
• No metabolic perturbations
• No movement disorders
• Rare reports: insomnia, irritability 8
• No significant drug interactions reported

Integration with Treatment Guidelines

The American College of Physicians guidelines 9, 10, 11 recommend second-generation antidepressants as first-line pharmacotherapy, with modification of treatment if inadequate response within 6-8 weeks. L-methylfolate fits as a second-step augmentation strategy when initial antidepressant monotherapy fails 9.

Note: L-methylfolate is not included in major ACP depression guidelines 9, 12, 10, 12, 11, which focus on standard antidepressants, psychotherapy, and omega-3 fatty acids. However, the research evidence [1-8] supports its use as adjunctive therapy.

Practical Implementation

Treatment Algorithm:

1. Confirm MDD diagnosis with structured interview
2. Initiate SSRI/SNRI at therapeutic dose
3. Assess response at 6-8 weeks
4. If inadequate response: Add L-methylfolate 15 mg daily
5. Continue both medications for minimum 60 days
6. Reassess with PHQ-9 or HAM-D at 8-12 weeks
7. If response achieved: continue indefinitely as maintenance

Monitoring:

• Depression severity: PHQ-9 or HAM-D every 2-4 weeks
• Functional impairment: work/home/social functioning
• Medication satisfaction scores
• No specific laboratory monitoring required for L-methylfolate itself

Key Caveats

• Not for monotherapy: Evidence inadequate for L-methylfolate alone without antidepressant 4
• Dose matters: Only 15 mg daily shows consistent efficacy; 7.5 mg ineffective 4
• Medical food status: Not FDA-approved drug; prescribed as medical food for metabolic deficiency
• Cost considerations: May not be covered by insurance as medical food rather than medication
• Pediatric use: Limited evidence in children/adolescents with unclear benefit 6